1,300 mg of aspirin daily does not cause positive fecal hemoccult tests.

Journal of Clinical Gastroenterology (Impact Factor: 3.2). 05/1983; 5(2):123-5. DOI: 10.1097/00004836-198304000-00006
Source: PubMed

ABSTRACT Americans 50 years of age and older are advised to test their stools for occult blood to detect colorectal neoplasms. Many will be taking 1,300 mg of aspirin daily because of cerebrovascular disease or smaller amounts for cardiovascular disease. To determine if 1,300 mg of aspirin causes positive hemoccult II tests, 27 healthy volunteers ate a red meat-free, high-fiber diet. Their stools were negative for occult blood during a 3-day control period and remained negative while they took 1,300 mg aspirin daily for an additional 7 days. This indicates that 1,300 mg aspirin daily for 1 week does not cause positive hemoccult II testing. Those taking this dose of aspirin probably need not interrupt therapy to perform hemoccult II testing.

  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine the effect of anticoagulants and antiplatelet medications on the positive-predictive-value of fecal occult blood test (FOBT). All patients who underwent a colonoscopy at our institution from 1995 to 2006 for a positive FOBT were identified. Medical records were searched, and patients were stratified into five groups selected a priori: low-dose aspirin, NSAIDs, warfarin, clopidogrel, or controls. The positive-predictive-value of FOBT for advanced colonic neoplasia was computed for each group. During the study period, 1,126 patients underwent colonoscopy for a positive FOBT and met entry criteria. The average age of study participants was 69 years and most were men. The positive-predictive-value of FOBT for advanced colon neoplasia was significantly higher in the control group (30.5%) when compared to those on low-dose aspirin (20.5%; p = 0.003), NSAIDs (19.7%; p = 0.003), clopidogrel (7.3%; p = 0.002), or warfarin (20%; p = 0.05). The positive-predictive-value of FOBT was significantly lower for those on clopidogrel than those on low-dose aspirin (p = 0.04) and NSAIDs (p = 0.05), but not warfarin (p = 0.08). The positive-predictive-value for FOBT was similar for those on aspirin, NSAIDs, and warfarin. There was a linear trend between the number of number of positive FOBT cards and prevalence of advanced colon neoplasia (p = 0.01). Anticoagulants and antiplatelet medications lower the positive-predictive-value of FOBT for advance colonic neoplasia and should be stopped if clinically feasible prior to stool collection.
    Digestive Diseases and Sciences 03/2010; 55(6):1637-42. · 2.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are several approaches to the early detection of colorectal cancer that currently are in use in various segments of the health care system. Herein, the status of cancer control research regarding symptom and risk factor assessment, sigmoidoscopy and colonoscopy, double contrast barium enema, and fecal occult blood testing is reviewed. In addition to the different technologies of early cancer detection, there are different models of disease control intervention. These include the routine clinical activities of primary care providers as well as programmatic screening of mass populations. The currently available techniques for early colorectal cancer detection appear better suited for existing patient care settings than for programs outside the direct supervision and follow-up of the health professional.
    Seminars in Surgical Oncology 02/1986; 2(4):215-24.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the evidence concerning gFOBT kits and to develop gFOBT standards to be implemented by the Ontario Colorectal Cancer (CRC) Screening Program (the "Program"). We evaluated 3 aspects of gFOBT kits: 1) performance factors; 2) usability factors; and 3) laboratory factors. We obtained information from the published literature, other countries that use gFOBT, the internet, and gFOBT kit manufacturers' instructions. The Program should use a single brand of gFOBT kit with sensitivity > or =40% and specificity > or =95% for the detection of CRC in repeated testing. The Program should regularly monitor gFOBT performance. Participants should not restrict their diets except for eliminating vitamin C supplements and citrus fruits and juices for 3 days prior to and during stool collection; participants should not discontinue taking aspirin (ASA) or non-steroidal anti-inflammatory drugs (NSAIDs). The Program should use one or a limited number of labs; leak-proof envelopes should be used that protect samples during mailing; the lab should delay processing fecal samples for at least 48 h following stool collection; the lab should implement staff training and quality control protocols. The Program should monitor and report on its performance according to these standards, and should continually assess new evidence related to CRC screening methods.
    Clinical biochemistry 09/2008; 41(16-17):1289-305. · 2.02 Impact Factor